FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.
GSK got permission faster than expected to sell a new lung cancer medicine that targets a specific type of cancer. This shows the medicine works well, which could help GSK's business and means doctors have a new option for sick patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.